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Introduction 
 
Despite Food and Drug Administration (FDA) 
approval in 2006, the Human Papillomavirus 
(HPV) vaccine continues to have the lowest 
completion rate of any vaccine in the United 
States (Reagan-Steiner et al., 2015). Data from 
the Centers for Disease Control and Prevention 
(CDC) show that in California, only 48% of 
females and 31% of males completed the three-
dose HPV vaccine series (Reagan-Steiner et al., 
2015). These rates remain well below the 
Healthy People 2020 initiative’s target goal of 
80% coverage (Department of Health and 
Human Services, 2013). Although professional 
medical agencies including the CDC Advisory 
Committee on Immunization Practices (ACIP) 
and the American Academy of Pediatrics (AAP) 
recommend routine HPV vaccination for 
females and males aged 11 or 12 years for 
protection against anogenital warts and certain 
cancers (cervical, vulvar and vaginal cancer in 
females, penile cancer in males, and anal cancer 
and oropharyngeal cancers in both females and 
males) (2012; Markowitz et al., 2014; Petrosky 
et al., 2015), health care provider vaccine 
practices vary. While everyone is at risk, the 
majority affected by HPV disease are 
underserved racial and ethnic minority groups, 
reflecting inherent disparities in patient access to 
treatment for HPV-related complications (Kaiser 
Family Foundation, 2015). 
 
Potential Barriers to Adolescent HPV 
Vaccination 
There may be several reasons for low HPV 
vaccine uptake. Missed opportunities during 
health care visits (Dempsey,Cohn,Vanessa & 
Mack, 2011; Gellin, 2015) is highlighted as a 
major barrier by the National Cancer Institute. 
One reason is inadequate provider time for 
explaining the need for early vaccination 
(Perkins et al., 2014). Given the time constraints 
of the modern-day medical visit, discussion 
devoted to HPV is frequently a low priority, 
leaving little time to address parents’ concerns 
(potential vaccine side effects, allergic reactions, 
and whether the vaccine promotes sexual 
activity) y (Perkins et al., 2013; Brewer et al., 
2007). Despite these concerns, there is no 
evidence to suggest that HPV vaccines are 
unsafe or promote sexual behaviors (Gee et al., 
2011; Jena,Goldman & Seabury, 2015; Stokley 
et al., 2014).  
 
Another missed opportunity is provider 
ambivalence in recommending the HPV vaccine 
(Hopfer & Clippard, 2010; Rosenthal et al., 
2010; Weiss, Zimet, Rosenthal,Brenneman & 
Klein, 2010). Providers may hesitate when 
insurance coverage is questionable or if 
extensive paperwork is needed, particularly in 
safety net clinics. Lack of HPV discussion may 
give parents the perception that vaccination is 
optional and less important than other adolescent 
vaccines (Perkins et al., 2014). Problem-focused 
clinic visits have the highest proportion of 
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missed opportunities for vaccination (91-98%), 
but even in prevention- focused visits, where 
vaccination is preferentially offered, missed 
opportunities are still common (61-92%) 
(Dempsey et al., 2011). 
  
The responsibility for low vaccination rates rests 
not only with providers and parents, but also 
with state level policies 
(Omer,Peterson,Curran,Hinman & Orenstein, 
2014). Data are clear that state-mandated school 
immunization requirements have significantly 
contributed to improving rates of vaccination 
coverage among adolescents (Omer,Pan & 
Halsey, 2007). However, policy alone will not 
suffice to increase HPV vaccination. Novel 
communication strategies (Downs, 2014; Miller-
Day & Hecht, 2013) are needed to increase 
acceptance among the general public, given  the 
current attitudes and beliefs surrounding HPV 
vaccination; the voluntary nature of the vaccine, 
lack of awareness (Almeida,Tiro,Rodriguez & 
Diamant, 2012), and general vaccination 
resistance (Opel et al., 2013), particularly in 
California.  
 
Solutions and Consequences  
Increasing HPV vaccination will require a 
multifaceted approach. This includes training 
health care providers on communication 
strategies to minimize missed opportunities and 
engage parents in the discussion, implementing 
school mandates through state level legislation, 
using prompt reminder systems, developing 
strategic communication to address distrust and 
reach resistant subgroups, and expanding HPV 
vaccine access outside of the traditional medical 
encounter.  
 
Addressing missed opportunities at health care 
visits offers the greatest hope for improving 
vaccine coverage. Providers must provide a 
strong and clear recommendation. The HPV 
vaccine must be treated the same as other age-
based recommended vaccines such as tetanus, 
diphtheria, acellular pertussis (Tdap) and 
meningococcal conjugate (MCV), and not as an 
option contingent upon adolescents’ current 
sexual activity status. To prompt providers to 
recommend the HPV vaccine, electronic health 
record provider reminder systems can be used. 
Recent studies show that such prompt systems 
can improve HPV vaccination rates, (Rand et al., 
2015; Ruffin et al., 2015; Szilagyi et al., 2015) 
but only 16% of pediatric practices use them 
(Rand et al., 2015).   
 
Addressing mistrust and reaching resistant 
subgroups of the population will require novel 
communication strategies, such as peer leader 
social network intervention approaches 
(Campbell & Salathe, 2013; Salathe & 
Khandelwal, 2011; Simmons et al., 2015). We 
know from communication theory the 
importance of trust in our sources when adopting 
and advocating recommended public health 
prevention measures. Concerns of the general 
public have been a consistent barrier in 
successful adoption of vaccination programs, 
especially when they are volitional (Kahn & 
Rickerts, 2015). Interventions must build 
communication and trust with targeted 
communities using culturally resonant and 
linguistically competent messages (Miller-Day 
& Hecht, 2013; Won,Middleman,Auslander & 
Short, 2015).  
 
To prepare parents for their children’s first dose 
of HPV vaccine, HPV infection counseling 
should be included as part of anticipatory 
guidance. Reframing HPV from the 
“promiscuity vaccine” or “STI vaccine” in the 
media to an anti-cancer vaccine can circumvent 
the association with sexual behavior. Parents 
may refuse the vaccine stating that their children 
are not yet sexually active. Postponing the 
vaccine not only increases the risk of disease in 
our children, but also perpetuates the perception 
to parents that vaccination is optional. We can 
build on lessons learned from the once 
controversial hepatitis B vaccine, which is now 
the universally accepted, to teach about HPV.  
 
Another strategy for closing the gap includes 
recommending HPV vaccination when 
adolescents make clinic visits for other vaccines 
such as meningitis or flu. Expanding access to 
venues outside of the traditional medical office 
to school-based health centers, pharmacies, 
safety net health clinics, and public health 
departments can promote further opportunities 
for vaccination. This has been shown to be 
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successful in our state (Tiro et al., 2012). 
Strengthening available Immunization 
Information Systems will allow schools and 
pharmacies to view and query patient 
immunization records to recommend and 
provide timely vaccination (Gellin, 2015).  
 
Mandates requiring HPV vaccine for school 
entry is another option. A policy implemented at 
the school level will bypass any 
sociodemographic disparities and guarantee that 
no child will be disproportionately vulnerable to 
HPV-related disease. California is beginning to 
eliminate personal and religious belief vaccine 
exemptions for children in public school, though 
HPV is not included (SB 277). In 2007, at least 
24 states and D.C. introduced legislation to 
specifically mandate the HPV vaccine for school 
(California withdrew its bill). We must applaud 
Rhode Island for joining Washington DC and 
Virginia in incorporating all CDC recommended 
vaccines (including HPV) into their school 
immunization regulations, and hope it will gain 
traction in the local media and spread to 
California.  
 
 
 
Conclusion 
 
The HPV vaccine should not be treated 
differently than other age-based routinely 
recommended vaccines. In order to truly make 
HPV vaccine part of standard care, we need to 
improve provider practices and policies, 
improve knowledge on vaccine myths and 
benefits, and expand access to the vaccine.  
Routine HPV vaccination in schools is a way to 
automate and improve uptake, and we can only 
hope that the message behind the recent Rhode 
Island HPV vaccine mandate will gain traction 
in the local media and spread to California. 
Lawmakers, educators, and scientists who 
support universal HPV vaccination must 
continuously communicate with, educate, and 
partner with community members on new 
mandates such as with HPV vaccination to 
improve health literacy and public health. 
Community members who believe in the HPV 
vaccine can further provide pressure on 
lawmakers to solve the low HPV vaccine uptake 
issue in California. None of us should have to 
suffer from diseases that can be avoided, 
especially when the solution is within our grasp. 
We have a vaccine that can prevent cancer—so 
let’s make sure we use it. 
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